To test the hypothesis that inhibition of NRF2 could improve the anti-tumor effect of ferroptosis inducers in ovarian cancer cells, we knocked down NRF2 through stable transduction of shRNA targeting NFE2L2 (Fig. 1D and s-Fig. 1A). This evidence concerns the gene NFE2L2 and ovarian cancer.